Logo image of FWP

FORWARD PHARMA A/S-ADR (FWP) Stock Fundamental Analysis

NASDAQ:FWP - Nasdaq - US34986J2042 - ADR - Currency: USD

1.95  +0.14 (+7.73%)

After market: 1.5 -0.45 (-23.08%)

Fundamental Rating

2

Overall FWP gets a fundamental rating of 2 out of 10. We evaluated FWP against 561 industry peers in the Biotechnology industry. While FWP has a great health rating, there are worries on its profitability. FWP has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year FWP has reported negative net income.
FWP had a negative operating cash flow in the past year.
FWP Yearly Net Income VS EBIT VS OCF VS FCFFWP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 0 200M 400M 600M 800M 1B

1.2 Ratios

The profitability ratios for FWP are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FWP Yearly ROA, ROE, ROICFWP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 200 400 600 800 1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for FWP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FWP Yearly Profit, Operating, Gross MarginsFWP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 20 40 60 80

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for FWP has been increased compared to 1 year ago.
There is no outstanding debt for FWP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
FWP Yearly Shares OutstandingFWP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M
FWP Yearly Total Debt VS Total AssetsFWP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 50M 100M 150M

2.2 Solvency

FWP has an Altman-Z score of 189.78. This indicates that FWP is financially healthy and has little risk of bankruptcy at the moment.
FWP's Altman-Z score of 189.78 is amongst the best of the industry. FWP outperforms 99.84% of its industry peers.
FWP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 189.78
ROIC/WACCN/A
WACCN/A
FWP Yearly LT Debt VS Equity VS FCFFWP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 200M 400M 600M 800M

2.3 Liquidity

FWP has a Current Ratio of 117.44. This indicates that FWP is financially healthy and has no problem in meeting its short term obligations.
FWP's Current ratio of 117.44 is amongst the best of the industry. FWP outperforms 100.00% of its industry peers.
FWP has a Quick Ratio of 117.44. This indicates that FWP is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 117.44, FWP belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 117.44
Quick Ratio 117.44
FWP Yearly Current Assets VS Current LiabilitesFWP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M

More info and screens

0

3. Growth

3.1 Past

FWP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 71.10%, which is quite impressive.
EPS 1Y (TTM)71.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.76%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
FWP Yearly Revenue VS EstimatesFWP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 200M 400M 600M 800M 1B
FWP Yearly EPS VS EstimatesFWP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

FWP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FWP Price Earnings VS Forward Price EarningsFWP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FWP Per share dataFWP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for FWP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FORWARD PHARMA A/S-ADR

NASDAQ:FWP (12/27/2022, 8:27:04 PM)

After market: 1.5 -0.45 (-23.08%)

1.95

+0.14 (+7.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-14 2022-04-14
Earnings (Next)N/A N/A
Inst Owners0%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap191.62M
Analysts45
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.71
P/tB 2.71
EV/EBITDA N/A
EPS(TTM)-0.02
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0
BVpS0.72
TBVpS0.72
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 117.44
Quick Ratio 117.44
Altman-Z 189.78
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)71.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.76%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-14.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y58.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y58.61%
OCF growth 3YN/A
OCF growth 5YN/A